Enhertu Shows Six-Month PFS Gain In HER2-Mutant Lung Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu reduced disease progression risk by 37% compared with pembrolizumab plus chemotherapy in a Phase III trialAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in prog…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.